Adaptimmune (ADAP)

Adaptimmune

The time to redefine the treatment of cancer is now.

About Us

Redefining the treatment of solid tumor cancers.

Adaptimmune is committed to treating the most challenging solid tumors using a proprietary cell therapy platform that harnesses a patient's cells to combat their cancer.

Using a personalized approach that has the potential to radically improve the patient experience.

We use cell therapy, a promising yet complex area of science, to engineer a person’s own cells to fight cancer.

A future where a single infusion could reshape cancer care.

We are a fully integrated company on the verge of a new era. With our first BLA submitted to the FDA, we are aiming to commercialize the  first engineered T-cell therapy in solid tumors to help improve cancer treatment.

SEC Filing Details

Document Details

Form

10-Q

Filing Date

Aug 12, 2020

Document Date

Jun 30, 2020

Form Description

Quarterly report which provides a continuing view of a company's financial position

Filing Group

Quarterly Filings

Company

TCR2 Therapeutics

Issuer

TCR2 THERAPEUTICS INC.

Filing Formats

View HTML

Download PDF

Download DOC

Download XLS

XBRL

XBRL Viewer

EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA

EX-101.CAL - XBRL TAXONOMY EXTENSION CALCULATION LINKBASE

EX-101.DEF - XBRL TAXONOMY EXTENSION DEFINITION LINKBASE

EX-101.LAB - XBRL TAXONOMY EXTENSION LABEL LINKBASE

EX-101.PRE - XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE

XML - XBRL INSTANCE DOCUMENT

Adaptimmune (ADAP)

Adaptimmune

The time to redefine the treatment of cancer is now.

About Us

Redefining the treatment of solid tumor cancers.

Adaptimmune is committed to treating the most challenging solid tumors using a proprietary cell therapy platform that harnesses a patient's cells to combat their cancer.

Using a personalized approach that has the potential to radically improve the patient experience.

We use cell therapy, a promising yet complex area of science, to engineer a person’s own cells to fight cancer.

Adaptimmune

Our fight with cancer is personal.

The time to redefine the treatment of cancer is now.

Redefining the treatment of solid tumor cancers.

Using a personalized approach that has the potential to radically improve the patient experience.

A future where a single infusion could reshape cancer care.

SEC Filing Details

Document Details

Filing Formats

XBRL

Adaptimmune

Our fight with cancer is personal.

The time to redefine the treatment of cancer is now.

Redefining the treatment of solid tumor cancers.

Using a personalized approach that has the potential to radically improve the patient experience.

A future where a single infusion could reshape cancer care.